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Figure: Boxplot of the bladder volumes for each patient 
In the five lipiodol patients we found that the COM of the 
lipiodol depended on the bladder volume and the location of 
the lipiodol in the bladder. Based on this correlation we 
developed a model to predict the position of the lipiodol 
using the bladder volume. We calculated a margin based on 
the actual position of the lipiodol, and subsequently we 
calculated a margin based on the difference between the 
actual and the predicted position, Table. 
 
 
 
Conclusion: As confirmed in the literature the full bladder 
protocol does not result in a stable bladder filling, and the 
displacement in cranial-anterior direction was the largest. 
Taking the predicted location of the tumour volume into 
account in preparing the treatment plans of the day, a 
considerable reduction in margin is achieved. Therefore, we 
need daily on-line adaptive treatment to adequately treat 
the bladder. 
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Purpose or Objective: To evaluate interfraction volume 
changes and dose variations of organs at risk (OAR) and to 
develop individualized radiotherapy (iRT) concepts with 
movement compensation. This work analyzes the potential 
benefit of adaptive planning in patients with prostate 
carcinoma. 
 
Material and Methods: We analyzed 16 patients with 
prostate cancer treated with helical IMRT and daily image 
guidance. Eight patients received radiation after 
prostatectomy with a total dose of 68 Gy in 34 fractions 
(group A), and eight a definitive irradiation with a total dose 
of 76.5 Gy in 34 fractions (group B). OAR rectum and bladder 
were delineated on daily Megavoltage (MV)CTs With the 
Planned Adaptive software by Tomotherapy® (Accuray Inc., 
Sunnyvale, CA) we performed dose recalculations on the 
single fractions CTs and compared the summation dose with 
the original planned dose. Dose variations were analyzed by 
means of Dmedian, Dmean, Dmax, Dmin, V30, V40, V60, V70, 
V75, as well as the OAR volume. 
 
Results: Our evaluation is still ongoing. During treatment, 
rectum volume ranged from 62-223% (A: 62-157%, B: 63-223%) 
of its initial volume; bladder from 22-375% (A: 30-311%, B: 
22-375%). The mean of the Dmean in the rectum was 30.7 Gy 
and 37.2 Gy in group A and B, respectively; and for the 
bladder 26.4 Gy and 40.8 Gy. The dose statistics for the 
rectum was as follows: V30 22.2-90.2%, V40 14.2-80.5%, V60 
0.1-46.9%, only for group A: V70 1.0-22.3% and V75 0-7.2%. 
The statistics for the bladder are: V30 15.6-100.0%, V40 10.9-
100.0%, V60 3.8-89.8%, only for group A: V70 1.6-28.0%, V75 
0.5-19.4%. 
 
Conclusion: For patients with prostate cancer, relevant 
variations in volume of OAR, such as rectum and bladder, can 
be observed. Hence, corresponding dose variations occur. 
Adaptive replanning approaches have the potential to reduce 
the dose to OAR. However, which concept, e.g. “plan of the 
day” or fast online recalculation, will be the suitable solution 
for routine patient treatment needs to be assessed in further 
evaluations. 
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Purpose or Objective: To assess outcomes of patients with 
anal canal cancer treated with Intensity-Modulated Radiation 
Therapy (IMRT) after a long time follow-up. 
 
Material and Methods: From July 2007 to September 2015, 
233 patients were treated by IMRT for anal squamous cell 
carcinoma. In 2009, Volumetric Modulated Arc Therapy 
RapidArc (VMAT RA) rapidly became our usual way of 
radiation for this cancer. Radiotherapy consisted in delivering 
45 Gy in 1.8 Gy daily-fractions, 5 days a week, to the primary 
tumor and the risk area including pelvic and inguinal nodes 
(PTV1). A second plan of 14.4-20 Gy was administered to the 
primary tumor (PTV2) in 1.8-2 Gy daily-fractions, also 5 days 
a week (Image 1), or by pulsed-dose rate interstitial 
brachytherapy for some T1 and T2. PTV1 and PTV2 were 
treated continuously without gap and without Simultaneously 
Integrated Boost (SIB). Concurrent chemotherapy based on 
5FU-mitomycin (MMC) or cisplatin was added for locally 
advanced tumors. Toxicities were evaluated according to the 
Common Toxicity Criteria for Adverse Events 4.0 scale. The 
survival estimates and their associated CI95% were calculated 
using the Kaplan-Meier method. We present here the first 166 
patients’ outcomes. 
 
 
 
Results: Median follow-up was 46,7 months CI95% [41,2-
51,6]. 124 women (75%) and 42 men (25%) were analysed. 
Median age was 61 years (range, 36-92). Tumors were 
classified as stages I, II, III and IV in 13%, 25%, 57% and 4% of 
the cohort, respectively. 13 patients were 
immunocompromised, 10 of those were HIV-positive (6%). 
Radiochemotherapy (RCT) or radiotherapy alone (RT) was 
delivered in 132 (80%) and 34 (20%) patients, respectively: 
104 (79%) MMC, 25 (19%) cisplatin and 3 (2%) other regimens. 
21 patients (13%) had the PTV2 treated by brachytherapy. 
162 patients (97,6%) were complete responders. 36 patients 
(21.7%) had a relapse : 20 local (56%) among which were 3 
synchronous metastatic failures, 4 locoregional (11%) and 12 
metastatic without any local failure (33%). 33 patients (20%) 
had a colostomy following radiotherapy : 17 (46%) for local 
relapse, 12 (32%) for radiation toxicity, 3 (8%) for an 
uncomplete response, 1 (2,7%) for tumor complications 
during RCT. Concerning late toxicities: no grade 4 was 
observed; grade 3 were diarrhea (1 patient), proctitis (11), 
vaginal stricture (5), hematuria (1), fecal incontinence (4), 
chronic radiodermatitis (2 patients); 28 cases of grade 2 
occurred among those clinical categories. About the 
hematologic late toxicity, there wasn’t any significative 
difference between the blood count prior to treatment and 
the recent one (p=0.23). The 3-year overall survival rate was 
85.5% CI95% [78.7-90.3], cancer-specific survival 89,0% CI95% 
[82,5-93,1], disease-free survival 74.6% CI95% [67-80.8], 
